ESSA Pharma

Developing the
Next Generation of
Treatments for
Prostate Cancer

About ESSA

ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer.  ESSA’s lead clinical candidate, masofaniten (formerly EPI-7386), represents a new approach to disrupting the androgen receptor signaling pathway, the primary driver of prostate cancer growth.

Learn More

Science

ESSA’s investigational therapies are designed to disrupt the androgen receptor (AR) signaling pathway, the primary pathway that drives prostate cancer growth, and prevent AR activation through selective binding to the N-terminal domain, a region of the AR that is not currently targeted by other therapies.

Events &
Presentations

Clinical Trials

Mark Markowski, MD, PhD Associate Professor of Oncology, Johns Hopkins Kimmel Cancer Center in Baltimore, discusses ESSA’s Phase 2 masofaniten (EPI-7386) + enzalutamide clinical trial with UroToday.

Ronald Tutrone, MD, FACS, CPI Director of Research, Chesapeake Urology, discusses ESSA’s Phase 2 masofaniten (EPI-7386) + enzalutamide clinical trial with UroToday.

Andrew Laccetti, MD, MS Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses ESSA’s Phase 1 masofaniten (EPI-7386) + enzalutamide clinical trial results on OncLive.

Monotherapy Study

Phase 1 trial of EPI-7386 in patients with castration-resistant prostate cancer (CRPC).

Monotherapy Study

Russell Pachynski, MD, Associate Professor of Medicine, Washington University School of Medicine in St. Louis, discusses ESSA’s Phase 1 EPI-7386 monotherapy clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.

Combination Study

Phase 1/2 trial of EPI-7386 with enzalutamide in patients with metastatic CRPC (mCRPC).

Combination Study

Andrew Laccetti, MD, MS, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses ESSA’s Phase 1/2 EPI-7386 + enzalutamide combination clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.

Learn More